Sahajanand Medical Technologies Shares List at 8% Premium on NSE
Sahajanand Medical Technologies made its debut on the stock exchanges on Friday, October 23, 2026, with its shares listing above the IPO issue price. On the NSE, the stock opened at ₹373 per share, an 8.43% premium over the issue price of ₹344. On the BSE, it began trading at ₹368.05 per share, registering a 6.99% premium.
The company’s ₹475.48 crore IPO was open for subscription from October 15 to October 19, 2026. The issue witnessed robust investor demand, attracting subscriptions 14.21 times the total shares on offer by the end of the bidding period.
Sahajanand Medical Technologies IPO - Issue Details
- Issue Type: Book Built Issue (OFS only)
- Total Issue Size: Up to ₹475.48 crore
- Fresh Issue: Not Applicable
- Offer for Sale (OFS): Up to ₹475.48 crore
- Face Value: ₹1 per equity share
- Price Band: ₹327 to ₹344 per share
- Lot Size: 43 shares
- Minimum Investment Amount (Retail Investor): ₹14,792 (43 shares at the upper price)
- Listing: BSE, NSE
- Book Running Lead Managers: Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited, Nuvama Wealth Management Limited
- Registrar: MUFG Intime India Private Limited
Explore other Upcoming IPOs on BSE and NSE.
Sahajanand Medical Technologies IPO Overall Subscription Status
[October 19, 2026, 7:00 P.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
34.70x |
|
Non-Institutional Investors (NIIs) |
14.64x |
|
Retail Individual Investors (RIIs) |
3.04x |
|
Employees |
0.37x |
|
Total |
14.21x |
About Sahajanand Medical Technologies Limited
Established in 2001, Sahajanand Medical Technologies specialises in the development and manufacture of medical devices, supported by a focus on research and development. Its portfolio includes products for vascular and structural heart procedures, such as coronary stents and balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs).
In FY2026, the company’s products reached 77 countries. During the three months ended June 30, 2026, it distributed its products across 65 countries, including India.
Key Financial Highlights
|
Particulars |
For the three month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Revenue from operations |
351.67 |
1,210.50 |
1,024.88 |
|
EBITDA |
48.58 |
170.65 |
128.02 |
|
Profit After Tax (PAT) |
15.09 |
69.08 |
25.15 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here